<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864094</url>
  </required_header>
  <id_info>
    <org_study_id>2019/374</org_study_id>
    <secondary_id>2019-000965-19</secondary_id>
    <nct_id>NCT03864094</nct_id>
  </id_info>
  <brief_title>Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine.</brief_title>
  <acronym>VH</acronym>
  <official_title>&quot;Haemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Equipotent Prophylactic Doses of Ephedrine, Phenylephrine, Norepinephrine vs Placebo.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Fonna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial the investigators want to examine if there is any difference in hemodynamic
      stability when giving equipotent prophylactic injections of ephedrine 0,1 mg/kg,
      phenylephrine 1 microg/kg, norepinephrine 0,1 microg/kg or sodium chloride (NaCl) 9 mg/ml
      during induction of general anesthesia with propofol and remifentanil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LiDCOplus monitoring system (Lithium Dilutional Cardiac Output (LiDCO) Ltd., Cambridge,
      United Kingdom) is a minimally invasive monitor for measuring stroke volume (SV) using two
      different algorithms. The PulseCO (PulseCO â„¢, Cambridge, United Kingdom) is based on analyses
      of the the arterial pressure wave giving nominal values. The LiDCO uses lithium-dilution for
      calibration to give absolute values. In this trial, the investigators will use the PulseCO
      looking at relative changes in uncalibrated hemodynamic variables. Continual changes in
      systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure
      (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular
      resistance (SVR) will be measured.

      Earlier studies have shown that propofol 2.5 mg/kg induction without opioid reduces CO
      (-15%), SV (-5 %), MAP (-33%) and SVR (-11%) and a slight reduction i HR. High-dose
      remifentanil anesthesia (2 microg/kg/min), in coronary patients reduced cardiac index (-25%),
      SV (-14%) and MAP (-39%) in a similar manner as propofol/remifentanil (propofol target 2
      microg/ml and remifentanil 0.5 microg/kg/min), but systemic vascular resistance index
      decreased (-14%) in propofol/remifentanil combination.

      Several procedures have been proposed to minimize the negative hemodynamic changes during
      induction. Administration of a crystalloid or a colloid did not prevent the decrease in MAP
      after induction of general anesthesia with propofol and fentanyl.

      The hemodynamic effects in propofol-fentanyl anesthesia of preoperative ephedrine 0.07-0.15
      mg/kg vs phenylephrine 1.5 microg/kg in valve surgery and concludes that ephedrine 0.07-0.1
      mg/kg is safe and effective in counteracting hypotension. A dose of 0.15 mg/kg ephedrine is
      suggested for preventing hypotension during anesthesia induction with propofol 2.5 mg/kg and
      remifentanil 3 microg/kg.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, double-blind.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 04Vaso). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in SBP during induction as measured by the LiDCOplus monitoring system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in HR during induction as measured by the LiDCOplus monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume (SV)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in SV during induction as measured by the LiDCOplus monitoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output (CO)</measure>
    <time_frame>First 7,5 minutes from a start of induction</time_frame>
    <description>Change in CO during induction as measured by the LiDCOplus monitoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance (SVR)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in SVR during induction as measured by the LiDCOplus monitoring system</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Hemodynamic Instability</condition>
  <condition>Anesthesia, General</condition>
  <condition>Anesthesia, Intravenous</condition>
  <arm_group>
    <arm_group_label>Ephedrine Propofol Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic Ephedrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine Propofol Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic Phenylephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine Propofol Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic Norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride Propofol Remifentanil</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>NaCl Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <description>0,1 mg/kg</description>
    <arm_group_label>Ephedrine Propofol Remifentanil</arm_group_label>
    <other_name>Ephedrine Sulphate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>1 microg/kg</description>
    <arm_group_label>Phenylephrine Propofol Remifentanil</arm_group_label>
    <other_name>Phenylephrine Hydrocloride Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>0,1 microg/kg</description>
    <arm_group_label>Norepinephrine Propofol Remifentanil</arm_group_label>
    <other_name>Noradrenalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>0,1 ml/kg</description>
    <arm_group_label>Sodium chloride Propofol Remifentanil</arm_group_label>
    <other_name>Sodium Chloride 0,9% injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>2 mg/kg</description>
    <arm_group_label>Ephedrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Norepinephrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Phenylephrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Sodium chloride Propofol Remifentanil</arm_group_label>
    <other_name>Propolipid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>1,7 microg/kg</description>
    <arm_group_label>Ephedrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Norepinephrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Phenylephrine Propofol Remifentanil</arm_group_label>
    <arm_group_label>Sodium chloride Propofol Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women

          -  Age 18-50 years

          -  Gynecological procedures

          -  General anesthesia

        Exclusion Criteria:

          -  Pre-existing hypertension

          -  Diabetes for several years

          -  Ischemic heart disease

          -  Cerebrovascular disease

          -  Heart valve disease

          -  Verified cardiac arrhythmia

          -  Anaemia

          -  Kidney or hepatic disease

          -  Hypersensitivity for soya, eggs or peanuts

          -  Pregnancy

          -  Poor health state

          -  Illicit substance use

          -  BMI &lt;20 or &gt;35 kg/m2

          -  SBP &gt;150 mmHg

          -  HR &gt;100 beats/min
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar SjÃ¸en, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Fonna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haldis Ã˜kland Lier</last_name>
    <phone>004752732000</phone>
    <email>haldis.johanne.okland.lier@helse-fonna.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Berit Haaland</last_name>
    <phone>0047 52732602</phone>
    <email>Berit.Haaland@helse-fonna.no</email>
  </overall_contact_backup>
  <reference>
    <citation>Fairfield JE, Dritsas A, Beale RJ. Haemodynamic effects of propofol: induction with 2.5 mg kg-1. Br J Anaesth. 1991 Nov;67(5):618-20.</citation>
    <PMID>1751277</PMID>
  </reference>
  <reference>
    <citation>Kazmaier S, Hanekop GG, Buhre W, Weyland A, Busch T, Radke OC, Zoelffel R, Sonntag H. Myocardial consequences of remifentanil in patients with coronary artery disease. Br J Anaesth. 2000 May;84(5):578-83.</citation>
    <PMID>10844832</PMID>
  </reference>
  <reference>
    <citation>Turner RJ, Gatt SP, Kam PC, Ramzan I, Daley M. Administration of a crystalloid fluid preload does not prevent the decrease in arterial blood pressure after induction of anaesthesia with propofol and fentanyl. Br J Anaesth. 1998 Jun;80(6):737-41.</citation>
    <PMID>9771299</PMID>
  </reference>
  <reference>
    <citation>Al-Ghamdi A. Hydroxyethylstarch 6% preload does not prevent the hypotension following induction with propofol and fentanyl. Middle East J Anaesthesiol. 2004 Jun;17(5):959-68.</citation>
    <PMID>15449752</PMID>
  </reference>
  <reference>
    <citation>El-Tahan MR. Preoperative ephedrine counters hypotension with propofol anesthesia during valve surgery: a dose dependent study. Ann Card Anaesth. 2011 Jan-Apr;14(1):30-40. doi: 10.4103/0971-9784.74397.</citation>
    <PMID>21196672</PMID>
  </reference>
  <reference>
    <citation>Masjedi M, Zand F, Kazemi AP, Hoseinipour A. Prophylactic effect of ephedrine to reduce hemodynamic changes associated with anesthesia induction with propofol and remifentanil. J Anaesthesiol Clin Pharmacol. 2014 Apr;30(2):217-21. doi: 10.4103/0970-9185.130024.</citation>
    <PMID>24803761</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helse Fonna</investigator_affiliation>
    <investigator_full_name>Gunnar Helge SjÃ¸en</investigator_full_name>
    <investigator_title>Consultant in Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Cardiac Output (CO)</keyword>
  <keyword>Systolic Blood Pressure (SBP)</keyword>
  <keyword>Systemic Vascular Resistance (SVR)</keyword>
  <keyword>Heart Rate (HR)</keyword>
  <keyword>Stroke Volume (SV)</keyword>
  <keyword>Lithium Dilutional Cardiac Output (LiDCO)</keyword>
  <keyword>Minimal Invasive Hemodynamic Monitor</keyword>
  <keyword>Propofol</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Ephedrine</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>Norepinephrine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>LiDCO-csv raw data and processed data will be made public at the publishers site, and the supporting information by request to the Principal Investigator. Statistical Data Plan is included in Study Protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be stored for 15 years after end of study, and may be shared during this time frame.</ipd_time_frame>
    <ipd_access_criteria>The data may be shared by contacting the Principal Investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

